Sign in
Not yet recruitingPhase 2

An All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)

Key facts

Who runs it
First Affiliated Hospital of Zhejiang University
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
30 people, planned
Starts
15 Dec 2026
Expected to end
14 Dec 2028
Type of study
Interventional
Treatments tested
  • Ivosidenib, Sonrotoclax, Chidamide
Record updated
13 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Patients with newly diagnosed AML. Diagnosis based on the 2022 WHO classification
  • Age >=18 years
  • Presence of an IDH1 R132 mutation (R132H, R132C, R132G, R132S, or R132L) confirmed by real-time quantitative PCR or NGS
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (see Appendix 1)
  • Echocardiographic LVEF >=45%; QTc interval <450 ms (males) or <470 ms (females)
  • Renal function: creatinine clearance >=50 mL/min (calculated using the Cockcroft-Gault formula or measured via 24-hour urine collection)
  • Liver function: aspartate aminotransferase (AST) <=3× ULN*; alanine aminotransferase (ALT) <=3× ULN*; total bilirubin <=1.5× ULN* (*unless attributed to leukemic infiltration)
  • Male patients, women of childbearing potential (women are considered non-childbearing only if postmenopausal for at least 12 months), and their partners voluntarily agree to use contraceptive measures deemed effective by the investigator during treatment and for at least 12 months after the last dose of the study drug
  • Patient or guardian agrees to participate in the clinical trial and signs the informed consent form

Who cannot take part

  • Patients previously treated with anthracyclines, or those with prior treatment involving IDH1 inhibitors, BCL-2 inhibitors (e.g., venetoclax), or HDAC inhibitors (e.g., chidamide)
  • Subjects who have received treatment with strong or moderate CYP3A inducers/inhibitors within 5 half-lives (or within 7 days) prior to the start of study treatment
  • Subjects known to be infected with HIV (HIV testing will be performed at screening in accordance with local guidelines or institutional standards)
  • Subjects with active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (defined as testing positive for the virus and having abnormal liver function)
  • Subjects with a New York Heart Association (NYHA) functional classification > Class II. Class II is defined as heart disease where the patient has no symptoms at rest but experiences fatigue, palpitations, dyspnea, or angina during ordinary physical activity
  • Subjects with chronic respiratory disease requiring continuous supplemental oxygen
  • Patients unable to take oral medication or those with malabsorption syndrome
  • Presence of uncontrolled systemic infection (viral, bacterial, or fungal)
  • Acute promyelocytic leukemia (APL/M3); core-binding factor AML (CBF-AML) with t(8;21), inv(16), or t(16;16)
  • Patients with AML known to involve the central nervous system (CNS)
  • Inability to sign the informed consent form

About the trial

What the trial wants to find out

This prospective, multicenter, exploratory clinical study is designed to evaluate the efficacy and safety of an all-oral combination of ivosidenib, sonrotoclax, and chidamide in adults with newly diagnosed acute myeloid leukemia (AML) harboring an IDH1 R132 mutation.

Read full original descriptionShow less

Approximately 30 participants aged 18 years or older will be enrolled. Eligible participants must have previously untreated AML with a confirmed IDH1 R132 mutation and adequate heart, liver, and kidney function. Ivosidenib targets the abnormal IDH1 protein, sonrotoclax blocks BCL-2, a protein that helps leukemia cells survive, and chidamide affects gene regulation and may increase the sensitivity of leukemia cells to treatment. The study hypothesis is that combining these three medicines may produce deep and durable remissions with an acceptable safety profile while providing a treatment that can be taken entirely by mouth.

Treatment will be given in 28-day cycles. During induction treatment, all participants will receive oral ivosidenib, sonrotoclax, and chidamide. In the initial exploratory stage, participants will be assigned in a 1:1:1 ratio to one of three induction schedules. The schedules differ in the planned duration of sonrotoclax and chidamide treatment. A bone marrow examination will be performed on Day 10 or Day 14, depending on the assigned schedule, to determine whether sonrotoclax and/or chidamide should be continued through Day 28. Early remission results, adverse events, and overall tolerability will be reviewed to select a recommended induction schedule for the expansion stage.

Participants who achieve a response will receive at least three 28-day cycles of consolidation treatment with the three-drug combination. Treatment duration may be shortened or the next cycle may be delayed if blood cell counts recover slowly or other clinically important side effects occur. After consolidation, measurable residual disease (MRD) will be assessed. MRD refers to the small number of leukemia cells that may remain after treatment even when remission has been achieved. Participants who become negative for IDH1 MRD will proceed to maintenance treatment with oral ivosidenib for up to 2 years. Participants with persistent IDH1 MRD may receive additional consolidation treatment, and allogeneic hematopoietic stem cell transplantation may be considered according to the protocol and clinical assessment.

The primary outcome is the 1-year event-free survival rate, defined by whether participants remain alive without relapse or disease progression. Secondary outcomes include the composite complete remission rate after induction treatment, MRD clearance and the time to MRD clearance, relapse-free survival, overall survival, and exploratory biological markers. Safety will be evaluated by recording adverse events and monitoring blood counts, bone marrow findings, liver and kidney function, electrocardiograms, and other clinically indicated tests. Participants will be followed regularly during treatment and follow-up.

The group in the trial

  • ArmTreatment being tested

    Ivosidenib, Chidamide, Sonrotoclax

    Treatment: Ivosidenib, Sonrotoclax, Chidamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Prospective, Exploratory Study Evaluating an All-oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for the Treatment of Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Record updated
13 November 2026